We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Rheumatology

Journal Scan / Research · October 21, 2021

HLA-DRB1 Risk Alleles for RA Are Associated With Different Responsiveness to Abatacept and Adalimumab

Arthritis research & therapy

 

Additional Info

Arthritis research & therapy
HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA
Arthritis Res. Ther. 2021 Sep 18;23(1)245, W Rigby, JH Buckner, S Louis Bridges, M Nys, S Gao, M Polinsky, N Ray, V Bykerk

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading